Cargando…
Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo
Modulation of the gut microbiota is a trending strategy to improve health. While butyrate has been identified as a key health-related microbial metabolite, managing its supply to the host remains challenging. Therefore, this study investigated the potential to manage butyrate supply via tributyrin o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054277/ https://www.ncbi.nlm.nih.gov/pubmed/36982942 http://dx.doi.org/10.3390/ijms24065859 |
_version_ | 1785015632463396864 |
---|---|
author | Van den Abbeele, Pieter Goggans, Mallory Deyaert, Stef Baudot, Aurélien Van de Vliet, Michiel Calatayud Arroyo, Marta Lelah, Michael |
author_facet | Van den Abbeele, Pieter Goggans, Mallory Deyaert, Stef Baudot, Aurélien Van de Vliet, Michiel Calatayud Arroyo, Marta Lelah, Michael |
author_sort | Van den Abbeele, Pieter |
collection | PubMed |
description | Modulation of the gut microbiota is a trending strategy to improve health. While butyrate has been identified as a key health-related microbial metabolite, managing its supply to the host remains challenging. Therefore, this study investigated the potential to manage butyrate supply via tributyrin oil supplementation (TB; glycerol with three butyrate molecules) using the ex vivo SIFR(®) (Systemic Intestinal Fermentation Research) technology, a highly reproducible, in vivo predictive gut model that accurately preserves in vivo-derived microbiota and enables addressing interpersonal differences. Dosing 1 g TB/L significantly increased butyrate with 4.1 (±0.3) mM, corresponding with 83 ± 6% of the theoretical butyrate content of TB. Interestingly, co-administration of Limosilactobacillus reuteri ATCC 53608 (REU) and Lacticaseibacillus rhamnosus ATCC 53103 (LGG) markedly enhanced butyrate to levels that exceeded the theoretical butyrate content of TB (138 ± 11% for REU; 126 ± 8% for LGG). Both TB + REU and TB + LGG stimulated Coprococcus catus, a lactate-utilizing, butyrate-producing species. The stimulation of C. catus with TB + REU was remarkably consistent across the six human adults tested. It is hypothesized that LGG and REU ferment the glycerol backbone of TB to produce lactate, a precursor of butyrate. TB + REU also significantly stimulated the butyrate-producing Eubacterium rectale and Gemmiger formicilis and promoted microbial diversity. The more potent effects of REU could be due to its ability to convert glycerol to reuterin, an antimicrobial compound. Overall, both the direct butyrate release from TB and the additional butyrate production via REU/LGG-mediated cross-feeding were highly consistent. This contrasts with the large interpersonal differences in butyrate production that are often observed upon prebiotic treatment. Combining TB with LGG and especially REU is thus a promising strategy to consistently supply butyrate to the host, potentially resulting in more predictable health benefits. |
format | Online Article Text |
id | pubmed-10054277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100542772023-03-30 Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo Van den Abbeele, Pieter Goggans, Mallory Deyaert, Stef Baudot, Aurélien Van de Vliet, Michiel Calatayud Arroyo, Marta Lelah, Michael Int J Mol Sci Article Modulation of the gut microbiota is a trending strategy to improve health. While butyrate has been identified as a key health-related microbial metabolite, managing its supply to the host remains challenging. Therefore, this study investigated the potential to manage butyrate supply via tributyrin oil supplementation (TB; glycerol with three butyrate molecules) using the ex vivo SIFR(®) (Systemic Intestinal Fermentation Research) technology, a highly reproducible, in vivo predictive gut model that accurately preserves in vivo-derived microbiota and enables addressing interpersonal differences. Dosing 1 g TB/L significantly increased butyrate with 4.1 (±0.3) mM, corresponding with 83 ± 6% of the theoretical butyrate content of TB. Interestingly, co-administration of Limosilactobacillus reuteri ATCC 53608 (REU) and Lacticaseibacillus rhamnosus ATCC 53103 (LGG) markedly enhanced butyrate to levels that exceeded the theoretical butyrate content of TB (138 ± 11% for REU; 126 ± 8% for LGG). Both TB + REU and TB + LGG stimulated Coprococcus catus, a lactate-utilizing, butyrate-producing species. The stimulation of C. catus with TB + REU was remarkably consistent across the six human adults tested. It is hypothesized that LGG and REU ferment the glycerol backbone of TB to produce lactate, a precursor of butyrate. TB + REU also significantly stimulated the butyrate-producing Eubacterium rectale and Gemmiger formicilis and promoted microbial diversity. The more potent effects of REU could be due to its ability to convert glycerol to reuterin, an antimicrobial compound. Overall, both the direct butyrate release from TB and the additional butyrate production via REU/LGG-mediated cross-feeding were highly consistent. This contrasts with the large interpersonal differences in butyrate production that are often observed upon prebiotic treatment. Combining TB with LGG and especially REU is thus a promising strategy to consistently supply butyrate to the host, potentially resulting in more predictable health benefits. MDPI 2023-03-20 /pmc/articles/PMC10054277/ /pubmed/36982942 http://dx.doi.org/10.3390/ijms24065859 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Van den Abbeele, Pieter Goggans, Mallory Deyaert, Stef Baudot, Aurélien Van de Vliet, Michiel Calatayud Arroyo, Marta Lelah, Michael Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo |
title | Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo |
title_full | Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo |
title_fullStr | Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo |
title_full_unstemmed | Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo |
title_short | Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo |
title_sort | lacticaseibacillus rhamnosus atcc 53103 and limosilactobacillus reuteri atcc 53608 synergistically boost butyrate levels upon tributyrin administration ex vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054277/ https://www.ncbi.nlm.nih.gov/pubmed/36982942 http://dx.doi.org/10.3390/ijms24065859 |
work_keys_str_mv | AT vandenabbeelepieter lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo AT goggansmallory lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo AT deyaertstef lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo AT baudotaurelien lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo AT vandevlietmichiel lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo AT calatayudarroyomarta lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo AT lelahmichael lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo |